Abiraterone Acetate - Zytiga - Biotech, Pharma and Life Science Channel
On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prostate cancer (CPRC) following failed Taxotere (docetaxel) therapy. This comes after the approval of three molecules for the treatment of prostate cancer in 2010, Jevtana (cabazitaxel) from Sanofi-Aventis, Provenge (sipuleucel-T, a cancer vaccine) and Xgeva (denosumab). These were the first molecules to gain approval since Taxotere, an anti-mitotic chemotherapy, in 2006.
News Articles
Clinical trial tests targeting prostate cancer treatment
ANN ARBOR, Mich., May 23, 2013 /PRNewswire-USNewswire/ -- Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all...
RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the...
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Financing Reflects Encouraging Clinical Progress with Galeterone in Prostate Cancer Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developin...
EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months follow...
Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: AS MEDICAL RESEARCH FACES POTENTIA...
As Medical Research Faces Potential Cuts, Prostate Cancer Foundation Funds 21 Young Investigators
The Prostate Cancer Foundation (PCF) today announced 21 new Young Investigator awards to support the most innovative minds in the field of prostate cancer research and expand its...
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company will present preclinical...
EXTON, Pa., March 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that, despite the 2012...
BURLINGTON, Mass., March 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its recent ma...
Tokai Pharmaceuticals to Present New Galeterone Mechanism of Action Data at 2013 ASCO GU
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that new preclinical data demonstrating the diff...
Events
None
Companies
None
Clinical Trials
Study of Abiraterone Acetate in Patients With Prostate Cancer
This is a single arm, single center, dose escalating trial to evaluate the safety, tolerability, and recommended dose of abiraterone acetate administered orally, by continuous once-daily a...
Continuous Oral Abiraterone in Castration Resistant Prostate Cancer
Primary Objective: 1. To explore the effect of abiraterone on levels of testosterone and DHT in the bone marrow of patients with castrate resistant metastatic prostate cancer. Seco...
To evaluate anti-tumor effects and safety of CB7630 in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy
Phase I/II Study of Abiraterone Acetate in Hormone Refractory Prostate Cancer
This is an open label phase I/II study to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of an oral CYP17 (17alpha-hydroxylase and C17,20-lyase) inhibit...
Neo-adjuvant Abiraterone + LHRH Versus LHRH in Prostate Cancer
The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue ch...
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, leuprolide acetate, and goserelin, may lessen the amount of androgens...
To compare the total exposure of CB7630 administered in capsule formulation with that in tablet formulation in patients with prostate cancer under fasted and fed conditions
This is a multicenter, open label drug-drug interaction study of abiraterone acetate and prednisone in patients with metastatic CRPC.
The purpose of this research study is to determine the effects of abiraterone acetate plus leuprolide acetate and prednisone versus leuprolide acetate alone on hormone levels in the blood...
A QT/QTc and Multi-dose Pharmacokinetic (PK) Study of Abiraterone Acetate
This is a phase 1B study to determine the effect of abiraterone acetate and prednisone on the conduction of electricity in the heart and the blood levels of abiraterone acetate and abirate...
PubMed Articles
Management of Castrate Resistant Prostate Cancer-Recent Advances and Optimal Sequence of Treatments.
Until 2010, chemotherapy with docetaxel was the only approved agent for treatment of metastatic castrate resistant prostate cancer (mCRPC). Since then, the therapeutic landscape of mCRPC has changed r...
New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer.
Prior to 2010, the treatment options for castrate-resistant prostate cancer (CRPC) were limited. In the past 3 years, four new agents have been approved by the US Food and Drug Administration for use...
Enzalutamide for the treatment of prostate cancer.
Introduction: The FDA approval of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) in 2005 marked a major milestone, as it was the first approved agent for this disease that demon...
A validated stability-indicating LC-UV-ESI-MS analytical method was established to analyze abiraterone (ABR) and its potential degradation products (DPs) and was performed according to ICH guidelines....
Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma.
In the last few years, the treatment of castration-resistant prostate carcinoma (CRPC) has changed completely. The approval of docetaxel and subsequent investigation in this field have led to developm...
Management of metastatic castration-resistant prostate cancer: recent advances.
Metastatic prostate cancer remains a considerable therapeutic challenge; however, advances in clinical research have resulted in five new treatments in the last 2 years. The immunotherapy sipuleucel-T...
OBJECTIVE: First clinical experiences with abiraterone and cabazitaxel for the treatment of metastatic castration-resistant prostate cancer patients following docetaxel chemotherapy are reported. PATI...
Emerging novel therapies for advanced prostate cancer.
This review examines the development and efficacy of novel treatment options for advanced prostate cancer and discusses novel therapies that are on the horizon. Since the introduction of docetaxel as...
Advances in the management of high-risk localised and metastatic prostate cancer.
At the third annual Interactive Genitourinary Cancer Conference, held in Budapest from 30 April to 1 May 2011, the latest developments in the management of patients with high-risk localised and metast...
MDV3100 for the treatment of prostate cancer.
Introduction: MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously...
Videos
Prostate cancer: Abiraterone for progressive metastatic disease
This video is for men with progressive metastatic disease failing Taxotere. It explains another new option that can help improve survival. The drug is called...
